Since its introduction by Popovi ch and Mon crief ( I) more than 2 decades ago , co ntinuous amb ulatory peritonea l dialysis (CAPO) has rem ained the most common form of fir sl-linc dia lyti c Ihcrapy in Hong Kon g (2) . Desp ite its popularity, co mbati ng nutri tiona l problem s is still a cha lle nge to the prac ticing neph rologist (3) . Patien ts arc oft en prescribed a high -protein diet to achieve nitrogen bala nce. Man y patient s, howe ve r, experi ence anorexia ; and na usea and vomiti ng after food intake is frequ e ntly report ed in the clinic. Over time , these patient s lapse into a sta te of malnutrition. wh ich is negat ively correlated with surv ival (4) .
An important cau se of anore xic symptom s in CAPD is delayed gastr ic em ptying, whicb cou ld be the combined result of inc reased intrape ritoneal pressure co nsequ e nt upon the insti llation of dia lysi s fl uid , a nd a uto no mi c gastropathy secondary to the un de rlying ure mic and/or diabe tic state . Pre vi ou s s tud ies usin g radi onu c lide tech niq ue s that measured the ga str ic tra nsit time a fte r the ingest ion of a 99l11 tcc hnctium-labeled standard meal demonstrated prolo nged ga stri e e mp tyi ng in CAPD pati ent s co m pared w ith norma l co ntro ls, and ga stroparesis is more pronounced amon g ure mic diabetics (5).
To m iti g ate th e c li nica l impact of gastro pare si s , gastro intes tinal pro moti lity age nts are oft en pre scr ibed to CA PO patient s. Cisapride, a serotonin receptor ago nist with po tent prok inctic pro pert ies ori ginally de signed for severe gastroesophage al refl ux disease, is one of the most frequ ently used age nts amo ng CA PD patient s in the past decad e. The c linica l efficacy of ci sapride has hee n docu men ted in o ne study, wh ic h re po rted inc reased plas ma alb u min le vel s after tr eatm e nt in pe rsistently hypoalhuminemic chron ic dia lysis patients who had poo r gastric empt yi ng (6).
In 1995 , 2 yea rs a fter its a pproval by the US Foo d and Drug Admi n istrat io n (F DA), tbe re were "black box" warnings that ci sa pride (Propu lsid ®) could ca use lifethrea teni ng ca rd iac arrh yt hmias , nota b ly torsades de poi nt e s . in p ati en ts sus ce pt ib le e it he r beca use of co nc urre nt med ication s t hat inter fe re wi th ci sap ride metabolism or prolong the QT interval or because of other di sease s tha t pred ispo se to suc h a rrhyt h mia s . Th e se wa rni ngs, together w itb subse quent health alert s issu ed by the manu facturer, led to regulatory action in 1998 by the FDA that contraindicated the Lise of cisapride in such patie nts (7) . Fur tber data from the FDA Talk Paper TOO-14 (8), wh ich ind icat ed that as 01" Dece mber 3 1, 1999 , use o f ci sapri de wa s asso cia ted wit h 34 1 re ports of a rr hy t hm ia s an d 80 repo rt s of deat h, p rom pt ed its co mplete wit hdrawal from the US market in Jul y 2000.
Per haps the vig ilant rea der wou ld have not ed that the wi t hdrawa l o f ci sa pride in t he US was not e nt ire ly ev idence-based . A recen t study conducted in children on per ito nea l d ialysis foun d mil d hut sig nificant inc reases in QTc i nte rval s, w hi e b were mo stl y attr ib uted to co nco mitant medication s rather tha n cisapridc per se (9) . Whether cisapride is safe in the adult dialysis pop ulatio n remai ns largely unknow n. In this issue of the Hon g Kong Joumal 01" Ncphrology, Tsc cl al ( 10) addressed this issue by retro spec tively comparing the clinical outcom e of S5 c hro nic di a lysis patients who had rece ived cisapride versus that of 279 patients who had ne ver taken cisaprid c. Th c au thors found that the usc of cisapride, regar dl ess o f do sage , docs not increase mo rta lity. Ne ve rtheless. hyp oalbum inem ia and hypokale mia were ide ntified as independent predictors of mortality in patients who had taken ci sapride, Ironically, hypoalbum ine mia could well he the ver y rea son fo r prescribing a prokinctic agen t for these patients in the first place. Jknee. the clinician must ex ercise h is ow n ac ume n by tak ing the appropriate preca utio na ry measures wh ich , as T se e t al have also partly poi nted ou t, incl ude (a) ca utiou s reapprai sa l of the ind ication of cisap ride : (b) detect ion of unrecognized unde rlying card iac disease or QT interval prolon gation ; (e) co rrec tio n of a ny pro-arrh yt hmi c e lec t ro ly te d isturba nces before prescription; (d} judiciou s re view of co n comi tan t me d icat io n s t hat may int e r act w it h ci sa pridc; (e) serial mon itoring of the QT interv al and serum potassium leve l after co mmenci ng treatment ; and (f) co nsta nt evaluatio n of the ind icat io n o f co nti nuin g tbe prescript ion .
W he re arc th e poten tia l p itfall s in p ha rm aco lo g ic interac tio n ? In ge ne ra l, c isaprid e mu st not be coad mini stcred wi th agen ts that po ssess e it her of the followin g two major pharmacok inetic/pharmacodynamie propert ies : (a) inhibi tors of cy toc h ro me P4 50 -3A4 en zy me s (C Y P-3A4) suc h as mac ro lid es ( I I ), new antidepressants particularly nefazodone and fluvoxarnine ( 12) , azo le antimycot ics, dilti azem , cimetadine, and ison iazid. The rationale is that CYP-3A4 is the primary mode of cisapride metabolism. As such, attention must a lso be d ra wn to t he rece nt ide n t ificat io n o f epoxy bergamott in as a CYP-3A4 inhibitor in grapefruit ( 13) ; and (b) dru gs with arrbytbmoge nie poten tial that prolong the QT interval. such as class la/III (by Vaughan Will iam s cl a ss ifi c ati on ) a nt iarrhyt h m ic dr ugs particularly sotalol ( 14) , and the second-generation nonseda tive selective HI-recept or antihistamines suc h as loratadin e, terfenadine, astem izole (15) . T he rationale is th at the se dru gs s hare the same arr hyt hmoge nic mecb ani sm with c isupridc in QT prol on gati on by spec ific. high affinity blockade of the cardiac K+channel encoded by the buman ether-a-go-go-related gene (HERO) in chromosome 7 ( 16) .
What is the current status in Hong Kong? Following the withdrawa l of c isa pride in th e US , a "Prc pulsid! STANG (Cisa pri de) L im ite d Ac c e s s Pr o gramm e " wa s impl em ent ed in June 200 I to prevent potent ially fatal event s rel at ed to c is apr ide usage. T he mandat ory Programme Form that includes a thorou gh chec klist of co ntraindic atio ns mu st be signed by the phys ician, prefe ra bly a gas troe ntero log is t, a nd th e pa ti ent in qu adruplicate to be retained by the institution/clinic in the patient 's medical record, the pha rmacy. the dr ug supplier. and the patient. It is not surpris ing that after the enforce ment of such stringent procedu res. cisapri de has becom e a lmo st an exti nct item in thi s loc ality. Alternative prokin etic agents that the neph rologist may co nsider include do rnperido ne, rnetoclop ramide, and ery thromyci n. T he ideal prokine tic agent-on e th at restores gas tric motility without compro mising cardiac HERO ch ann el s and docs no t depend o n C YP-3A 4 eliminatio n-has yet to be form ulated.
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